Halozyme Therapeutics, Inc. (HALO)
71.55
+0.82
(+1.16%)
USD |
NASDAQ |
Jun 09, 14:58
Halozyme Therapeutics Research and Development Expense (Quarterly) : 25.56M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 961.60M |
| Agenus, Inc. | 11.82M |
| Altimmune, Inc. | 16.17M |
| Lineage Cell Therapeutics, Inc. | 4.234M |
| Amgen, Inc. | 1.719B |